BridgeBio Pharma, Inc. announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.
“UC Davis is a top-tier research university and we feel honored to get the chance to collaborate closely with the talented team there as we work to discover, create, test and deliver breakthrough medicines for people who are suffering from genetic diseases,” said BridgeBio founder and CEO Neil Kumar, Ph.D.
Under the agreement, the BridgeBio team will work closely with investigators at UC Davis to seek and evaluate potential research projects in genetic disease and precision oncology.
“We have a great appreciation for BridgeBio’s vision to create new pathways that connect innovative research to potential treatments for diseases that may not otherwise be pursued in the marketplace,” said Bill Tucker, interim associate vice chancellor for Innovation and Technology Commercialization at UC Davis. “We are thrilled to combine our expertise in the hope of expanding the impact of our research to help those in need.”
BridgeBio collaborates with stand-out academic institutions, including UC Davis, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date
Read the company’s full press release here